Physician profile
Jorge Asconape
NPI 1245200609
$108,750.48
in general payments reported to CMS, 2019-2025
8 companies · $9,785 in 2025
The $9,785 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $13K · 2021: $12K · 2022: $26K · 2023: $20K · 2024: $16K · 2025: $9,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $39K · Consulting Fee: $4,050 · Travel and Lodging: $1,771 · Food and Beverage: $740 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $38,950.00 |
| Consulting Fee | $4,050.00 |
| Travel and Lodging | $1,771.09 |
| Food and Beverage | $739.50 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $87,793.72 | 2020-2025 | Xcopri |
| Ucb, INC. | $11,294.64 | 2019-2021 | |
| Ucb Sa | $4,950.00 | 2021-2025 | Briviact |
| Eisai INC. | $3,243.77 | 2019 | |
| Medtronic USA, INC. | $1,402.68 | 2019 | |
| Neurelis, INC. | $35.95 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Supernus Pharmaceuticals, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Asconape listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.